BioWorld. Link to homepage.

Clarivate
  • BioWorld
  • BioWorld MedTech
  • BioWorld Asia
  • BioWorld Science
  • Data Snapshots
    • BioWorld
    • BioWorld MedTech
    • Infographics: Dynamic digital data analysis
    • Index insights
    • NME Digest
  • Special reports
    • Infographics: Dynamic digital data analysis
    • Trump administration impacts
    • Under threat: mRNA vaccine research
    • BioWorld at 35
    • Biopharma M&A scorecard
    • Bioworld 2025 review
    • BioWorld MedTech 2025 review
    • BioWorld Science 2025 review
    • Women's health
    • China's GLP-1 landscape
    • PFA re-energizes afib market
    • China CAR T
    • Alzheimer's disease
    • Coronavirus
    • More reports can be found here

BioWorld. Link to homepage.

  • Sign In
  • Sign Out
  • My Account
Subscribe
BioWorld - Sunday, January 4, 2026
Home » Blogs » BioWorld MedTech Perspectives » Fiscal cliff and the device tax: a second take

BioWorld MedTech Perspectives
BioWorld MedTech Perspectives RSS FeedRSS

BioWorld MedTech

Fiscal cliff and the device tax: a second take

Dec. 20, 2012
By Mark McCarty

As discussed previously, a repeal of the device tax faces longish odds. Opponents of the tax have punted to a suspension of the tax as was disclosed by a letter from nearly 20 members of the U.S. Senate, a move purportedly prompted by the short turn-around from the date of the IRS’s final rule to the effective date of the tax.

Despite the disclaimers, it’s important to point out that you clearly don’t believe a repeal has any chance in the short term if you’re arguing for a suspension. So let’s ask ourselves what sort of headwinds the device tax discussion faces in Washington.

Both President Obama and House Speaker John Boehner have their constituencies, which is only part of the reason it’s difficult to close the gap. There are, after all, serious ideological differences. The original battle lines were drawn at allowing the Bush-era tax cuts to lapse for those making more than $250,000 a year (Obama) versus no increases in tax rates (Boehner), and each of them has nudged a bit on that point.

Fiscal conservatives are still demanding more serious cuts to mandatory spending programs (Social Security and Medicare) than the White House has offered, however, and Obama has to reckon with his constituencies if he bends too much on that score. Rumor in Washington has it that Obama is loathe to bend too much this time around because of what is seen among liberals as too large a set of concessions in last year’s budget sequestration negotiations. After that legislation was agreed on, nearly everyone was up for re-election, making a final deal this year highly implausible because of … well, because of the election.

I might also point out that among those with the President’s ear is the doctor lobby, which everyone in Washington probably sees as a proxy for the senior vote, a constituency that’s not going anywhere anytime soon.

In response to the stalled fiscal cliff negotiations, Boehner indicated he would allow a Dec. 20 vote on a bill that would set the bar on income tax rate increases at $1 million, a level that a leading Democrat, Sen. Chuck Schumer, has endorsed. The problem is that this bill may pass the House, but has no chance in the Senate (which by the way has passed no spending bills at all for fiscal 2013).

The disingenuousness on the other side is even more brazen. President Obama used the slaughter of children at Sandy Hook in an attempt to get Republicans to capitulate in a televised set of comments on Dec. 19. It was breathtaking even by the standards in Washington, but Boehner is determined to push the bill onto the floor for a vote, and so it goes.

The problem for the device tax is that the intractability of the positions of the two sides, which has already clobbered any prospect of a repeal, now seems likely to kayo even a suspension.

There’s an old saying in the public relations business that states basically, “may your bad news be buried under even worse news.” Conversely, the prospect of your legislation being buried under something politically heftier is a problem, and is precisely the dilemma faced by opponents of the device tax.

Add to all this the fact that Obama has argued against even a hold-up in the device tax, and it’s tough to avoid the conclusion that the corpus formed to hold off the tax is either dead at the scene or in critical condition. The only thing that’ll save the patient now is a miracle. Those who are agnostic will not hold their breath.

Dec. 21 update: The House bill Boehner had hoped to pass, which would have set the tax bar at $1 million, was pulled due to lack of support. There is an exceedingly high probability at this point that Jan. 1 will arrive with no resolution to the fiscal cliff issues. Stock markets are reacting badly to the news, and U.S. debt instruments are snaring larger returns, which boosts the government's borrowing costs. Will Moody's further downgrade U.S. bonds as a result? The device tax suspension effort is buried, and so in all likelihood is the push for repeal.

Popular Stories

  • Today's news in brief

    BioWorld
    BioWorld briefs for Dec. 31, 2025.
  • Today's news in brief

    BioWorld MedTech
    BioWorld MedTech briefs for Jan. 2, 2026.
  • Sickle cell illustration

    AND-017 increases RBC and hemoglobin in sickle cell disease

    BioWorld Science
    Sickle cell disease (SCD) is an inherited hemoglobinopathy caused by a mutation in the gene encoding β-globin that results in hemoglobin S polymerization, red...
  • Businessman, businesswoman handshake

    Shionogi nabs revenue-generating ALS drugs with $2.5B Tanabe pact

    BioWorld
    Shionogi & Co. Ltd. will acquire global rights to U.S. FDA approved amyotrophic lateral sclerosis therapy edaravone through a $2.5 billion acquisition deal with...
  • Asia focused map inside light bulb

    Big pharma taps fast Asia innovation in search of next Keytruda

    BioWorld
    Speed and innovation from Asia Pacific’s (APAC) biotechnology sector had big pharma scouring the region for the next oncology heir to Keytruda (pembrolizumab),...
  • BioWorld
    • Today's news
    • Analysis and data insight
    • Clinical
    • Data Snapshots
    • Deals and M&A
    • Financings
    • Newco news
    • Opinion
    • Regulatory
    • Science
  • BioWorld MedTech
    • Today's news
    • Clinical
    • Data Snapshots
    • Deals and M&A
    • Financings
    • Newco news
    • Opinion
    • Regulatory
    • Science
  • BioWorld Asia
    • Today's news
    • Analysis and data insight
    • Australia
    • China
    • Clinical
    • Deals and M&A
    • Financings
    • Newco news
    • Regulatory
    • Science
  • BioWorld Science
    • Today's news
    • Biomarkers
    • Cancer
    • Conferences
    • Endocrine/Metabolic
    • Immune
    • Infection
    • Neurology/Psychiatric
    • NME Digest
    • Patents
  • More
    • About
    • Advertise with BioWorld
    • Archives
    • Article reprints and permissions
    • Contact us
    • Cookie policy
    • Copyright notice
    • Data methodology
    • Infographics: Dynamic digital data analysis
    • Index insights
    • Podcasts
    • Privacy policy
    • Share your news with BioWorld
    • Staff
    • Terms of use
    • Topic alerts
Follow Us

Copyright ©2026. All Rights Reserved. Design, CMS, Hosting & Web Development :: ePublishing